Advertisement

A guide to the anti-innovation “pharmaphobia” narrative for the aspiring innovator

  • Thomas P. Stossel
    Correspondence
    Reprint requests: Thomas P. Stossel, MD, Brigham & Women's Hospital, American Enterprise Institute, Harvard Medical School, Boston, MA 02118.
    Affiliations
    Brigham & Women's Hospital, Harvard Medical School, American Enterprise Institute, Boston, MA
    Search for articles by this author
      Thomas P. Stossel is an American Cancer Society Professor of Medicine Emeritus at Harvard Medical School, Honorary Physician in the Hematology Division of Brigham & Women's Hospital, founding scientist of BioAegis Therapeutics, Visiting Scholar of The American Enterprise Institute and cofounder of Options for Children in Zambia.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Zycher B.
        • DiMasi J.
        • Milne C.
        Private sector contributions to pharmaceutical science: thirty-five summary case histories.
        Am J Ther. 2010; 17: 101-120
        • Sampat B.
        • Lichtenberg F.
        What are the respective roles of the public and private sectors in pharmaceutical innovation?.
        Health Aff. 2011; 30: 332-339
        • Stossel T.
        Pharmaphobia: how the conflict of interest myth undermines American medical innovation.
        Rowman and Littlefield, Publishers, Lanham (MD), Boulder (CO), New York, London2015
        • DiMasi J.
        • Grabowski H.
        • Hansen R.
        Innovation in the pharmaceutical industry: new estimates of R&D costs.
        J Health Econ. 2016; 47: 20-33